Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Angiogenesis >  FLT3 inhibitors >  Dovitinib

Dovitinib

Basic information Safety Supplier Related

Dovitinib Basic information

Product Name:
Dovitinib
Synonyms:
  • 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
  • dovitinib
  • 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
  • CS-226
  • CHIR-258;CHIR 258
  • Unii-I35H55G906
  • CHIR258 7.7G
  • TKI-258
CAS:
405169-16-6
MF:
C21H21FN6O
MW:
392.43
EINECS:
1308068-626-2
Product Categories:
  • Inhibitors
  • Intermediates & Fine Chemicals
  • API intermediates
  • Pharmaceuticals
Mol File:
405169-16-6.mol
More
Less

Dovitinib Chemical Properties

Density 
1.386
storage temp. 
-20°
solubility 
Soluble in DMSO (up to 30 mg/ml).
pka
9.44±0.70(Predicted)
form 
solid
color 
Yellow-green
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
CAS DataBase Reference
405169-16-6
More
Less

Dovitinib Usage And Synthesis

Description

Dovitinib (405169-16-6) is a potent kinase inhibitor. Inhibits FLT3 (IC50 = 1 nM), c-KIT (IC50 = 2 nM), FGFR (IC50 = 8 nM), VEGFR1/2/3 (IC50 = 10 nM), PDGFRβ (IC50 = 27 nM), and CSF-1R (IC50 = 36 nM).1 Active in cell culture and in whole animals. Dovitinib selectively blocks the growth B9 cells transformed by wild type, or activated mutant FGFR3. Induces apoptosis, or sensitizes cells to induction of apoptosis by other means in a variety of cancer cell lines.

Uses

Compound used in treating melanoma

Uses

Dovitinib (TKI258, CHIR-258) is a multitargeted tyrosine kinase inhibitor of FLT3 and c-KIT with IC50 of 1 nM and 2 nM, respectively.

Uses

Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively.

Uses

Dovitinib is a receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor-2, basic fibroblast growth factor-1, and platelet-derived growth factor β receptors (IC50s = 65, 11, and 5 nM, respectively). At 0.04 μM, dovitinib can inhibit endothelial cell proliferation and motility. These antiangiogenic effects have been proposed to be the mechanism by which dovitinib inhibits hepatocellular carcinoma growth and metastasis. Dovitinib has been evaluated in clinical trials for the treatment of advanced solid tumors.

Definition

ChEBI: 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-quinolinone is a N-arylpiperazine.

in vivo

the combination of tigatuzumab and tki258 inhibited huh-7 xenograft tumor growth [3]. tki258 reduced wm tumor progression [4].

target

FLT3

References

1) Lee et al. (2005), In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models; Clin. Cancer Res., 11 3633 2) Xin et al. (2006), CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice; Clin. Cancer Res., 12 4908

DovitinibSupplier

Guangzhou Tomums Life Science Co., Ltd. Gold
Tel
020-31155029 18902330969
Email
sales@tomums.cn
Tianjin Kailiqi Biotechnology Co., Ltd. Gold
Tel
15076683720
Email
klq@cw-bio.com
Minglong (Xianning) Pharmaceutical Co., LTD Gold
Tel
155-7155-6913 15571556913
Email
354024111@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Yangzhou Siyu Chemical Co.,Ltd.
Tel
0514-87325867
Email
sales@siyuchem.com